Cargando…
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease, with minimal therapeutic options. Aberrant tyrosine kinase activity influences tumor growth and is regulated by phosphorylation. We investigated phosphorylated kinases as target in PDAC. METHODS: Mass spectrometry-based ph...
Autores principales: | Le Large, T. Y. S., Bijlsma, M. F., El Hassouni, B., Mantini, G., Lagerweij, T., Henneman, A. A., Funel, N., Kok, B., Pham, T. V., de Haas, R., Morelli, L., Knol, J. C., Piersma, S. R., Kazemier, G., van Laarhoven, H. W. M., Giovannetti, E., Jimenez, C. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941981/ https://www.ncbi.nlm.nih.gov/pubmed/33750427 http://dx.doi.org/10.1186/s13046-021-01892-z |
Ejemplares similares
-
Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment
por: Le Large, Tessa Ya Sung, et al.
Publicado: (2019) -
Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers
por: Mantini, G., et al.
Publicado: (2020) -
Multidrug‐resistant transporter expression does not always result in drug resistance
por: Le Large, Tessa Ya Sung, et al.
Publicado: (2018) -
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022) -
Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)